Pathologic changes in gonadotropin releasing hormone agonist analogue treated uterine leiomyomata
Objective: To define the pathologic changes underlying the mechanism of shrinkage of uterine leiomyomata in patients treated with luprolide acetate. Design: Retrospective study of pathologic changes seen in leiomyomata removed by hysterectomy or myomectomy in treated and untreated patients, matched...
Gespeichert in:
| Veröffentlicht in: | Fertility and sterility 1997-05, Vol.67 (5), p.837-841 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 841 |
|---|---|
| container_issue | 5 |
| container_start_page | 837 |
| container_title | Fertility and sterility |
| container_volume | 67 |
| creator | Deligdisch, Liane Hirschmann, Scott Altchek, Albert |
| description | Objective: To define the pathologic changes underlying the mechanism of shrinkage of uterine leiomyomata in patients treated with luprolide acetate.
Design: Retrospective study of pathologic changes seen in leiomyomata removed by hysterectomy or myomectomy in treated and untreated patients, matched by age and size of uteri and leiomyomata.
Patient(s): Gross description and histologic slides of 30 treated and 30 untreated patients.
Intervention(s): Histologic examination performed blindly (without knowledge of treatment). Statistical work-up using X
2 analysis with 1 df.
Main Outcome Measure(s): Degree of hyaline and hydropic degeneration, cellularity, nuclear atypia, necrosis, and obliteration of interface.
Result(s): Confluent nodular hyaline degeneration representing a scarlike retraction, geographic hydropic degeneration necrosis and obliteration of the interface between myoma and myometrium were found in higher proportions in the treated patients; differences in cellularity, nuclear atypia, and edema were not statistically significant.
Conclusion(s): The decrease in size of the treated leiomyomata occurs as an accelerated postmenopausal shrinkage because of the antiestrogenic effect of the therapy. Obliterated cleavage planes may explain the difficult enucleation of myomatous nodules in some of the treated patients. |
| doi_str_mv | 10.1016/S0015-0282(97)81394-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78957432</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0015028297813945</els_id><sourcerecordid>78957432</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-cbbb6ff99316175b42c1943072a3ee72be5fdeb02692eb2ffa382da430cb4e5d3</originalsourceid><addsrcrecordid>eNqFkF1rFDEUhoModVv9CYW5EKkXo_mYTCZXIqVWoWBBvQ4nmTO7kZlkTTJC_33T7rK3XoXD-7wnh4eQS0Y_Msr6Tz8pZbKlfOBXWn0YmNBdK1-QDZOyb2UvxUuyOSGvyXnOfyilPVP8jJxpJugwqA2Beyi7OMetd43bQdhibnxotjHAGEuK-zoknBGyD9tmF9MSAzZQc59LAwFqdcWmJISCY7MWTL4CM_q4PMQFCrwhryaYM749vhfk99ebX9ff2rsft9-vv9y1rhN9aZ21tp8mrQWrN0rbccd0J6jiIBAVtyinES3lveZo-TSBGPgIlXC2QzmKC_L-sHef4t8VczGLzw7nGQLGNRs1aKk6wSsoD6BLMeeEk9knv0B6MIyaJ7XmWa158ma0Ms9qjay9y-MHq11wPLWOLmv-7phDdjBPCYLz-YTxXkrFaMU-HzCsMv55TCY7j8Hh6BO6Ysbo_3PII_dFl-I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78957432</pqid></control><display><type>article</type><title>Pathologic changes in gonadotropin releasing hormone agonist analogue treated uterine leiomyomata</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Deligdisch, Liane ; Hirschmann, Scott ; Altchek, Albert</creator><creatorcontrib>Deligdisch, Liane ; Hirschmann, Scott ; Altchek, Albert</creatorcontrib><description>Objective: To define the pathologic changes underlying the mechanism of shrinkage of uterine leiomyomata in patients treated with luprolide acetate.
Design: Retrospective study of pathologic changes seen in leiomyomata removed by hysterectomy or myomectomy in treated and untreated patients, matched by age and size of uteri and leiomyomata.
Patient(s): Gross description and histologic slides of 30 treated and 30 untreated patients.
Intervention(s): Histologic examination performed blindly (without knowledge of treatment). Statistical work-up using X
2 analysis with 1 df.
Main Outcome Measure(s): Degree of hyaline and hydropic degeneration, cellularity, nuclear atypia, necrosis, and obliteration of interface.
Result(s): Confluent nodular hyaline degeneration representing a scarlike retraction, geographic hydropic degeneration necrosis and obliteration of the interface between myoma and myometrium were found in higher proportions in the treated patients; differences in cellularity, nuclear atypia, and edema were not statistically significant.
Conclusion(s): The decrease in size of the treated leiomyomata occurs as an accelerated postmenopausal shrinkage because of the antiestrogenic effect of the therapy. Obliterated cleavage planes may explain the difficult enucleation of myomatous nodules in some of the treated patients.</description><identifier>ISSN: 0015-0282</identifier><identifier>EISSN: 1556-5653</identifier><identifier>DOI: 10.1016/S0015-0282(97)81394-5</identifier><identifier>PMID: 9130887</identifier><identifier>CODEN: FESTAS</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Antineoplastic Agents, Hormonal - therapeutic use ; Biological and medical sciences ; Female ; Genital system. Reproduction ; GnRH agonist analogue therapy ; Humans ; Infant, Newborn ; Leiomyoma - drug therapy ; Leiomyoma - pathology ; Leiomyoma - surgery ; Leuprolide - therapeutic use ; Lymphocytes - pathology ; Medical sciences ; Middle Aged ; Myometrium - pathology ; Myometrium - surgery ; Necrosis ; nodular hyalinization ; Pharmacology. Drug treatments ; Retrospective Studies ; Uterine leiomyoma ; Uterine Neoplasms - drug therapy ; Uterine Neoplasms - pathology ; Uterine Neoplasms - surgery</subject><ispartof>Fertility and sterility, 1997-05, Vol.67 (5), p.837-841</ispartof><rights>1997</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-cbbb6ff99316175b42c1943072a3ee72be5fdeb02692eb2ffa382da430cb4e5d3</citedby><cites>FETCH-LOGICAL-c436t-cbbb6ff99316175b42c1943072a3ee72be5fdeb02692eb2ffa382da430cb4e5d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0015-0282(97)81394-5$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2655710$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9130887$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Deligdisch, Liane</creatorcontrib><creatorcontrib>Hirschmann, Scott</creatorcontrib><creatorcontrib>Altchek, Albert</creatorcontrib><title>Pathologic changes in gonadotropin releasing hormone agonist analogue treated uterine leiomyomata</title><title>Fertility and sterility</title><addtitle>Fertil Steril</addtitle><description>Objective: To define the pathologic changes underlying the mechanism of shrinkage of uterine leiomyomata in patients treated with luprolide acetate.
Design: Retrospective study of pathologic changes seen in leiomyomata removed by hysterectomy or myomectomy in treated and untreated patients, matched by age and size of uteri and leiomyomata.
Patient(s): Gross description and histologic slides of 30 treated and 30 untreated patients.
Intervention(s): Histologic examination performed blindly (without knowledge of treatment). Statistical work-up using X
2 analysis with 1 df.
Main Outcome Measure(s): Degree of hyaline and hydropic degeneration, cellularity, nuclear atypia, necrosis, and obliteration of interface.
Result(s): Confluent nodular hyaline degeneration representing a scarlike retraction, geographic hydropic degeneration necrosis and obliteration of the interface between myoma and myometrium were found in higher proportions in the treated patients; differences in cellularity, nuclear atypia, and edema were not statistically significant.
Conclusion(s): The decrease in size of the treated leiomyomata occurs as an accelerated postmenopausal shrinkage because of the antiestrogenic effect of the therapy. Obliterated cleavage planes may explain the difficult enucleation of myomatous nodules in some of the treated patients.</description><subject>Adult</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Genital system. Reproduction</subject><subject>GnRH agonist analogue therapy</subject><subject>Humans</subject><subject>Infant, Newborn</subject><subject>Leiomyoma - drug therapy</subject><subject>Leiomyoma - pathology</subject><subject>Leiomyoma - surgery</subject><subject>Leuprolide - therapeutic use</subject><subject>Lymphocytes - pathology</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myometrium - pathology</subject><subject>Myometrium - surgery</subject><subject>Necrosis</subject><subject>nodular hyalinization</subject><subject>Pharmacology. Drug treatments</subject><subject>Retrospective Studies</subject><subject>Uterine leiomyoma</subject><subject>Uterine Neoplasms - drug therapy</subject><subject>Uterine Neoplasms - pathology</subject><subject>Uterine Neoplasms - surgery</subject><issn>0015-0282</issn><issn>1556-5653</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkF1rFDEUhoModVv9CYW5EKkXo_mYTCZXIqVWoWBBvQ4nmTO7kZlkTTJC_33T7rK3XoXD-7wnh4eQS0Y_Msr6Tz8pZbKlfOBXWn0YmNBdK1-QDZOyb2UvxUuyOSGvyXnOfyilPVP8jJxpJugwqA2Beyi7OMetd43bQdhibnxotjHAGEuK-zoknBGyD9tmF9MSAzZQc59LAwFqdcWmJISCY7MWTL4CM_q4PMQFCrwhryaYM749vhfk99ebX9ff2rsft9-vv9y1rhN9aZ21tp8mrQWrN0rbccd0J6jiIBAVtyinES3lveZo-TSBGPgIlXC2QzmKC_L-sHef4t8VczGLzw7nGQLGNRs1aKk6wSsoD6BLMeeEk9knv0B6MIyaJ7XmWa158ma0Ms9qjay9y-MHq11wPLWOLmv-7phDdjBPCYLz-YTxXkrFaMU-HzCsMv55TCY7j8Hh6BO6Ysbo_3PII_dFl-I</recordid><startdate>19970501</startdate><enddate>19970501</enddate><creator>Deligdisch, Liane</creator><creator>Hirschmann, Scott</creator><creator>Altchek, Albert</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19970501</creationdate><title>Pathologic changes in gonadotropin releasing hormone agonist analogue treated uterine leiomyomata</title><author>Deligdisch, Liane ; Hirschmann, Scott ; Altchek, Albert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-cbbb6ff99316175b42c1943072a3ee72be5fdeb02692eb2ffa382da430cb4e5d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adult</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Genital system. Reproduction</topic><topic>GnRH agonist analogue therapy</topic><topic>Humans</topic><topic>Infant, Newborn</topic><topic>Leiomyoma - drug therapy</topic><topic>Leiomyoma - pathology</topic><topic>Leiomyoma - surgery</topic><topic>Leuprolide - therapeutic use</topic><topic>Lymphocytes - pathology</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myometrium - pathology</topic><topic>Myometrium - surgery</topic><topic>Necrosis</topic><topic>nodular hyalinization</topic><topic>Pharmacology. Drug treatments</topic><topic>Retrospective Studies</topic><topic>Uterine leiomyoma</topic><topic>Uterine Neoplasms - drug therapy</topic><topic>Uterine Neoplasms - pathology</topic><topic>Uterine Neoplasms - surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Deligdisch, Liane</creatorcontrib><creatorcontrib>Hirschmann, Scott</creatorcontrib><creatorcontrib>Altchek, Albert</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Fertility and sterility</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Deligdisch, Liane</au><au>Hirschmann, Scott</au><au>Altchek, Albert</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pathologic changes in gonadotropin releasing hormone agonist analogue treated uterine leiomyomata</atitle><jtitle>Fertility and sterility</jtitle><addtitle>Fertil Steril</addtitle><date>1997-05-01</date><risdate>1997</risdate><volume>67</volume><issue>5</issue><spage>837</spage><epage>841</epage><pages>837-841</pages><issn>0015-0282</issn><eissn>1556-5653</eissn><coden>FESTAS</coden><abstract>Objective: To define the pathologic changes underlying the mechanism of shrinkage of uterine leiomyomata in patients treated with luprolide acetate.
Design: Retrospective study of pathologic changes seen in leiomyomata removed by hysterectomy or myomectomy in treated and untreated patients, matched by age and size of uteri and leiomyomata.
Patient(s): Gross description and histologic slides of 30 treated and 30 untreated patients.
Intervention(s): Histologic examination performed blindly (without knowledge of treatment). Statistical work-up using X
2 analysis with 1 df.
Main Outcome Measure(s): Degree of hyaline and hydropic degeneration, cellularity, nuclear atypia, necrosis, and obliteration of interface.
Result(s): Confluent nodular hyaline degeneration representing a scarlike retraction, geographic hydropic degeneration necrosis and obliteration of the interface between myoma and myometrium were found in higher proportions in the treated patients; differences in cellularity, nuclear atypia, and edema were not statistically significant.
Conclusion(s): The decrease in size of the treated leiomyomata occurs as an accelerated postmenopausal shrinkage because of the antiestrogenic effect of the therapy. Obliterated cleavage planes may explain the difficult enucleation of myomatous nodules in some of the treated patients.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>9130887</pmid><doi>10.1016/S0015-0282(97)81394-5</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0015-0282 |
| ispartof | Fertility and sterility, 1997-05, Vol.67 (5), p.837-841 |
| issn | 0015-0282 1556-5653 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78957432 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adult Antineoplastic Agents, Hormonal - therapeutic use Biological and medical sciences Female Genital system. Reproduction GnRH agonist analogue therapy Humans Infant, Newborn Leiomyoma - drug therapy Leiomyoma - pathology Leiomyoma - surgery Leuprolide - therapeutic use Lymphocytes - pathology Medical sciences Middle Aged Myometrium - pathology Myometrium - surgery Necrosis nodular hyalinization Pharmacology. Drug treatments Retrospective Studies Uterine leiomyoma Uterine Neoplasms - drug therapy Uterine Neoplasms - pathology Uterine Neoplasms - surgery |
| title | Pathologic changes in gonadotropin releasing hormone agonist analogue treated uterine leiomyomata |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T03%3A24%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pathologic%20changes%20in%20gonadotropin%20releasing%20hormone%20agonist%20analogue%20treated%20uterine%20leiomyomata&rft.jtitle=Fertility%20and%20sterility&rft.au=Deligdisch,%20Liane&rft.date=1997-05-01&rft.volume=67&rft.issue=5&rft.spage=837&rft.epage=841&rft.pages=837-841&rft.issn=0015-0282&rft.eissn=1556-5653&rft.coden=FESTAS&rft_id=info:doi/10.1016/S0015-0282(97)81394-5&rft_dat=%3Cproquest_cross%3E78957432%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78957432&rft_id=info:pmid/9130887&rft_els_id=S0015028297813945&rfr_iscdi=true |